Has Neda Ashourian, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,427 in general payments to Neda Ashourian, MD across 95 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Neda Ashourian, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Neda Ashourian, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Neda Ashourian, MD

MOHS-Micrographic Surgery · Chicago, ILNPI 1922212539

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations.

$2,427in general payments, 2019–2025

Across 95 payments — averaging $25.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$521
Regeneron Healthcare Solutions, Inc.$503
Almirall LLC$271
Biofrontera Inc.$231
Pfizer$113
Galderma Laboratories, L.p.$101
plus $688 from 15 others

What the payments were for

Food & beverage$2,427100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	15	$521
Regeneron Healthcare Solutions, Inc.	18	$503
Almirall LLC	9	$271
Biofrontera Inc.	11	$231
Pfizer	6	$113
Galderma Laboratories, L.p.	6	$101
Genentech USA, Inc.	5	$95
Organogenesis Inc.	4	$91
Sanofi	2	$82
Sun Pharmaceutical Industries Inc.	3	$77
Novartis	2	$52
DUSA Pharmaceuticals, Inc.	2	$43
LEO Pharma Inc.	2	$42
UCB, Inc.	1	$39
Biowound Solutions, Inc.	2	$33
Helsinn Therapeutics (U.S.), Inc.	2	$32
Novum Pharma, LLC	1	$24
Aclaris Therapeutics, Inc.	1	$22
Bristol Myers Squibb	1	$22
Dermira, Inc.	1	$22
Ortho Dermatologics, A Division Of Bausch Health US, LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TEPEZZA$120

How this compares

$2,427 in reported general payments places this provider in the 55th percentile of 40 mohs-micrographic surgery providers in Illinois.

See all mohs-micrographic surgery providers in Illinois →

Medicare billing

Part B allowed, 2024

$945,500

Medicare patients

912

Services billed

9,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clobetasol Propionate	34	$2,248
Ketoconazole	102	$1,604
Fluorouracil	16	$1,275
ValacyclovirValacyclovir Hcl	32	$658
Cephalexin	85	$585
Gentamicin Sulfate	18	$525
Mupirocin	62	$445
Triamcinolone Acetonide	58	$440
Nystatin	11	$235
Doxycycline Hyclate	18	$168
Hydrocortisone	26	$152
Clotrimazole	11	$136
Levofloxacin	11	$41
Tramadol Hcl	15	$24

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Chicago

Todd JohnsonChicago$10K
Simon YooChicago$10K
Daniel SchlessingerChicago$8K
Aleksandar KrunicChicago$8K
Ross PearlmanChicago$8K
Sarah WilsonChicago$8K
Maxim PolanskyChicago$4K
Nour El-KashlanChicago$3K
Jean Christophe LapiereChicago$1K
Murad AlamChicago$1K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →